Last edition
News about "Lynelle B Hoch"
Bristol Myers Squibb Acquires Orbital Therapeutics
The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.
Lynelle B Hoch | 13/10/2025 | By Dineshwori | 139
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members